Timothy L. Comstock
About
In The Last Decade
Timothy L. Comstock
54 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 90
- Ophthalmology 1.6k
- Public Health, Environmental and Occupational Health 590
- Radiology, Nuclear Medicine and Imaging 541
- Pharmacology 250
- Pharmaceutical Science 136
Countries citing papers authored by Timothy L. Comstock
This map shows the geographic impact of Timothy L. Comstock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy L. Comstock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy L. Comstock more than expected).
Fields of papers citing papers by Timothy L. Comstock
This network shows the impact of papers produced by Timothy L. Comstock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy L. Comstock. The network helps show where Timothy L. Comstock may publish in the future.
Co-authorship network of co-authors of Timothy L. Comstock
This figure shows the co-authorship network connecting the top 25 collaborators of Timothy L. Comstock. A scholar is included among the top collaborators of Timothy L. Comstock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy L. Comstock. Timothy L. Comstock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 2 | |
| 3 | 28 | |
| 4 | Clinical efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against MRSA and MRSE | 1 |
| 5 | 11 | |
| 6 | 13 | |
| 7 | Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery | 7 |
| 8 | 5 | |
| 9 | Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis | 2 |
| 10 | Clinical Efficacy of Besifloxacin Ophthalmic Suspension; Integrated Microbiological Results of 3 Trials for Topical Treatment of Bacterial Conjunctivitis | 1 |
| 11 | Besifloxacin Ophthalmic Suspension 0.6% Is Safe and Well Tolerated in Patients With Bacterial Conjunctivitis | 2 |
| 12 | 65 | |
| 13 | 52 | |
| 14 | Ocular Pharmacokinetics of Besifloxacin, a Novel Fluoroquinolone Antimicrobial Agent for Topical Ophthalmic Use, in Healthy Volunteers | 2 |
| 15 | Fluocinolone Acetonide Intravitreal Implant to Treat Posterior Segment Uveitis: 3–Year Results of a Multi–Center Clinical Trial | 4 |
| 16 | 342 | |
| 17 | 1 | |
| 18 | 3 | |
| 19 | 26 | |
| 20 | 0 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.